Story perspectives

UK Negotiates Drug Prices Amid Controversial Trade Talks

11/5/2025

26 2

Summary

Story summary

The U.K. is negotiating drug prices with the Trump administration and pharmaceutical companies under the Voluntary Scheme for Pricing, Access and Growth (VPAG).
Britain has proposed increasing the NHS's payment threshold for medicines by up to 25%.
Pharmaceutical executives, including those from Eli Lilly, demand further changes before continuing a £279 million investment in a biotech project.
The negotiations also involve the government's "clawback" system, which mandates firms to repay revenue if NHS spending exceeds a cap.
These discussions are part of broader trade negotiations following a framework deal between Keir Starmer and Donald Trump in May.

1 of 1

Story summary

The U.K. is negotiating drug prices with the Trump administration and pharmaceutical companies under the Voluntary Scheme for Pricing, Access and Growth (VPAG).
Britain has proposed increasing the NHS's payment threshold for medicines by up to 25%.
Pharmaceutical executives, including those from Eli Lilly, demand further changes before continuing a £279 million investment in a biotech project.
The negotiations also involve the government's "clawback" system, which mandates firms to repay revenue if NHS spending exceeds a cap.
These discussions are part of broader trade negotiations following a framework deal between Keir Starmer and Donald Trump in May.